Colak Meryem, Sarzhanova Shakhnoza, Yegin Zeynep Arzu, Ozkurt Zubeyde Nur, Fidan Isil, Bozdayi Gulendam
Department of Medical Microbiology, Karabuk University Faculty of Medicine, Karabuk, Turkey.
Department of Medical Microbiology, Gazi University Faculty of Medicine, Ankara, Turkey; Department of Medical Microbiology, Ahmet Yesevi International Kazakh-Turkish University Faculty of Medicine, Turkistan, Kazakhstan.
Clin Lymphoma Myeloma Leuk. 2021 May;21(5):e488-e492. doi: 10.1016/j.clml.2021.01.023. Epub 2021 Feb 5.
Epstein-Barr virus (EBV) is associated with different types of human malignancies, including Burkitt lymphoma, nasopharyngeal carcinoma, and lymphomas. We retrospectively investigated the presence of EBV-DNA by real-time PCR in clinical samples of patients diagnosed as having hematologic malignancies while investigating the cause of lymphoproliferative disorders, and investigated its relationship to clinical manifestations.
Fifty clinical samples sent to Gazi University's hematology clinics between November 2013 and March 2018 were included. EBV-DNA was investigated by real-time PCR method, and EBV-IgM and EBV-IgG antibodies were investigated by ELISA.
Fifty serum samples were investigated, and 10% (5/50) EBV-DNA positivity was determined in patients. Of the 5 patients with EBV-DNA positivity, 2 had acute lymphoblastic leukemia, 1 lymphoma, 1 T-cell lymphoma, and 1 B-cell lymphoma. Concomitant EBV-DNA and viral capsid antigen (VCA)-IgM positivity was not detected. The VCA-lgM test results of the all EBV-DNA-positive patients were negative and VCA-IgG positive (except for 1 patient). Regarding virus load, of the 5 samples, 2, 1, 1, and 1 of the samples had a virus load of 10, 10, 10, and 10 copies/mL, respectively.
EBV infection is threatening in patients with hematologic malignancies and are diagnosed by serologic and molecular methods. As a result of the study, we suggest that the detection of EBV-DNA by real-time PCR in patients being admitted with lymphoproliferative diseases and diagnosed as acute lymphoblastic leukemia and lymphomas may be useful in follow-up and treatment.
爱泼斯坦-巴尔病毒（EBV）与多种人类恶性肿瘤相关，包括伯基特淋巴瘤、鼻咽癌和淋巴瘤。我们回顾性地通过实时聚合酶链反应（PCR）检测了被诊断为血液系统恶性肿瘤患者临床样本中EBV-DNA的存在情况，同时调查了淋巴增殖性疾病的病因，并研究了其与临床表现的关系。
纳入了2013年11月至2018年3月期间送往加齐大学血液科门诊的50份临床样本。采用实时PCR法检测EBV-DNA，采用酶联免疫吸附测定（ELISA）法检测EBV-IgM和EBV-IgG抗体。
共检测了50份血清样本，患者中EBV-DNA阳性率为10%（5/50）。在5例EBV-DNA阳性患者中，2例患有急性淋巴细胞白血病，1例患有淋巴瘤，1例患有T细胞淋巴瘤，1例患有B细胞淋巴瘤。未检测到EBV-DNA与病毒衣壳抗原（VCA）-IgM同时阳性的情况。所有EBV-DNA阳性患者的VCA-lgM检测结果均为阴性，VCA-IgG阳性（1例患者除外）。关于病毒载量，5份样本中，分别有2份、1份、1份和1份样本的病毒载量为10、10、10和10拷贝/毫升。
EBV感染对血液系统恶性肿瘤患者构成威胁，可通过血清学和分子方法进行诊断。研究结果表明，对因淋巴增殖性疾病入院并被诊断为急性淋巴细胞白血病和淋巴瘤的患者，通过实时PCR检测EBV-DNA可能有助于随访和治疗。
